参考文献 1. Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 2006; 15: 308-18 2. Xiang YJ, Dai SM. Prevalence of rheumatic diseases and disability in China. Rheumatol Int 2009; 29: 481–490. 3. Durosaro O, Davis MD, Reed KB, Rohlinger AL. Incidence of cutaneous lupus erythematosus, 1965-2005: a population-based study.Arch Dermatol. 2009 Mar;145(3):249-53. 4. Cervera R, Khamashta MA, Hughes GRV. The Euro-lupus project: epidemiology of systemic lupus erythematosus in Europe. Lupus 2009 (18), 869–874 5. Graham RR, Hom G, Ortmann W. Review of recent genome-wide ssociation scans in lupus. J intern Med. 2009 Jun; 265(6);680-8 6. Harley JB, Alarcon-Riquelme ME, Criswell LA et al. Genomewide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK,KIAA1542 and other loci. Nat Genet 2008; 40: 204–10. 7. Remmers EF, Plenge RM, Lee AT et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007; 357: 977–86. 8. Demirci FY, Manzi S, Ramsey-Goldman R et al. Association of a common interferon regulatory factor 5 (IRF5) variant with increased risk of systemic lupus erythematosus (SLE). Ann Hum Genet 2007; 71: 308–11. 9. Musone SL, Taylor KE, Lu TT et al. Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet 2008; 40: 1062–4. 10. Lee YH, Rho YH, Choi SJ et al. The PTPN22 C1858T functional polymorphism and autoimmune diseases – a meta-analysis.Rheumatology (Oxford) 2007; 46: 49–56. 11. Hom G, Graham RR, Modrek B et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX.N Engl J Med 2008; 358: 900–9. 12. Gateva V, Sandling JK. Hon G,et al.A large-scale roplication study identifies TNIP1. PRDM1, UHRF1BP1 and IL10 as a risk loci for systemic lupus erythematosus. Nat Genet. 2009 Nov;41(11);1228-33 13. Han JW, Zheng HF, Gui Y, et al. Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genett. 2009 Nov;41(11)1234-7 14. Lee-Kirsch MA, Gong M,chowdhury D. Mutation in the gene encoding the 3'-5' DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet. 2007 Sep; 39(9):1065-7 15. Sanchez E, Gomez LM, Lopez-Nevot MA, et al. Evidence of association of macrophage migration inhibitory factory factor gene polymorphisms with systemic lupus erythematosus. Gene Immun.2006 Jul;7(5):433-6 16. Pan Y, Sawalha AH. Epigenetic regulation and the pathogenesis of systemic lupus erythematosus. Transl Res 2009;153:4–10 17. Lu Q，Kaplan M，Ray D，Zacharek S，Gutsch D，Richardson B. Demethylation of ITGAL (CD11a) regulatory sequences in lupus. Arthritis Rheum, 2002;46(5):1282-91 18. Kaplan M, Lu Q, Wu A, Attwood J, Richardson B. Demethylation of promoter regulatory elements contributes to perforin overexpression in CD4+ lupus T cells. J Immunol, 2004; 172 (6):3652-61 19. Oelke K, Lu Q, Richardson D, Wu A, Richardson B. Overexpression of CD70 and overstimulation of IgG synthesis by lupus T cells and T cells treated with DNA methylation inhibitors. Arthritis Rheum, 2004;50(6):1850-60 20. Lu Q, Wu A, Tesmer L et al. Demethylation of CD40LG on the inactive X in T cells from women with lupus. J Immunol ,2007 ;179:6352–6358 21. Li Y, Zhao M, Luo Y, Zhao S, Zhang X, Heng Y, Long H, Su Y, Richardson B, Lu Q. Gadd45a overexpression contributes to autoimmunity by demethylating DNA in lupus T cells. Arthritis & Rheumatism, 2009;60(10): S216. 22. Zhao S, Wang Y, Liang Y, Long H, Ding S, Zhao M, Yin H, Lu Q. Differential MicroRNA expression and the contribution of MiR-126 to CD4+ T cell DNA hypomethylation in system lupus erythematosus. Arthritis & Rheumatism, 2009; 60(10): S40. 23. Zhao M, Gao F,Wu X, Tang J, Luo Y, Sun Y, Richardson B, Lu Q. RFX1 regulates the expression of CD11a and CD70 in CD4+ T cells of patients with systemic lupus erythematosus. Arthritis & Rheumatism, 2009; 60(10): S39. 24. Tang Y, Luo X, Cui H, et al. MicroRNA-146a contributes to abnormal activation of the type1 interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum. 2009 Apr; 60(4):1065-75 25. Van Bavel CC, Dieker J, Muller S, et,al. Apoptosis-associated acetylation on histone H2B is an epitope for lupus autoantibodies. Mol Immunol. 2009;47(2-3):511-6. 26. Hu N, Qiu X, Luo Y, Yuan J, Li Y, Lei W, Zhang G, Zhou Y, Su Y, Lu Q. Abnormal histone modification patterns in lupus CD4+ T cells. J Rheumatol. 2008;35(5):804-10. 27. Fillatreau S, Gray D, Anderton SM: Not always the bad guys: B cells as regulators of autoimmune pathology. Nat Rev Immunol 2008;8:391-397. 28. Lee J, Kuchen S, Fischer R, Chang S, Lipsky PE: Identification and characterization of a human CD5(+) pre-naive B cell population. J Immunol 2009, 182:4116-4126. 29. Jacobi AM, Mei H, Hoyer BF, Mumtaz IM,et,al. HLA-DRhigh/CD27high plasmablasts indicate active disease in patients with SLE. Ann Rheum Dis 2009, Feb 5. [Epub ahead of print]. 30. Jacobi AM, Reiter K, Mackay M, et,al. Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus - Delineation by expression of CD27, IgD, and CD95. Arthritis Rheum 2008, 58:1762-1773. 31. Lindh E, Lind SM, Lindmark E, et,al. AIRE regulates T-cell-independent B-cell responses through BAFF. Proc Natl Acad Sci U S A 2008;105:18466-18471. 32. Lee HY, Hong YK, Yun HJ et al. Altered frequency and migration capacity of CD4+CD25+ regulatory T cells in systemic lupus erythematosus. Rheumatol (Oxf) 2008; 47:789–794. 33. Yan B, Ye S, Chen G et al (2008) Dysfunctional CD4+ CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-alpha-producing antigen-presenting cells. Arthritis Rheum 58:801–812. doi:10.1002/art.23268 34. Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O,et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy：pilot study. Arthritis Res Ther，2006，8(3)：R83. 35. Tang H, Tan G, Guo Q, Pang R, Zeng F.Abnormal activation of the Akt-GSK3??signaling pathway in peripheral blood T cells from patients with systemic lupus erythematosus .Cell Cycle. 2009 Sep 1;8(17):2789-93. Epub 2009 Sep 6. 36. Zhao P, Xu L, Wang P, Liang X, et al. Increased expression of human T-cell immunoglobulinand mucin-domain-containing molecule-4 in peripheral blood mononuclear cells from patients with system lupus erythematosus. Cell Mol Immunol. 2010 Mar;7(2):152-6. Epub 2010 Feb 8. 37. Hu D, Liu X, Chen S, Bao C. et,al. Expressions of IL-18 and its binding protein in peripheral blood leukocytes and kidney tissues of lupus nephritis patients Clin Rheumatol. 2010 Feb 8. [Epub ahead of print] 38. Rong Zhang, Meifen Xing, Weiwen Wang, et,al. Effect of Interferon-alpha in systemic lupus erthematosus (SLE) serum on the differentiation and maturation of dendritic cells derived from CD34+ hematopoietic precursor cells. Journal of Nanjing Medical University, Volume 23, Issue 6, November 2009, Pages 380-385 39. Wong CK, Lit LC, Tam LS, et,al Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol 2008; 127:385–93. 40. Crispin JC, Oukka M, Bayliss G et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol 2008; 181:8761–6. 41. Bettelli E, Korn T, Oukka M, Kuchroo VK. Induction and effector functions of T(H)17 cells. Nature 2008; 453: 1051–7. 42. Stritesky GL, Yeh N, Kaplan MH. IL-23 promotes maintenance but not commitment to the Th17 lineage. J Immunol 2008; 181:5948–55. 43. Vogt B, Fuhrnrohr B, Muller R, Sheriff A. CRP and the disposal of dying cells: Consequences for SLE and rheumatoid arthritis. Autoimmunity 2007;40:295–298. 44. Toloza SM, Colo DE, Gladman DD. et al. Vitamin D insufficiency in a large female SLE cohort. Lupus. 2009 Nov 6.[Epub ahead of print] 45. Turchin I, Bernatsky S, Clarke AE, et al. Cigarette smoking and cutaneous damage in systemic lupus erythematosus. J Rheumatol.2009 Dec; 36(12):2691-3 46. Navratil JS, Manzi S, Kao AH, et al. Platelet C4d is highly specific for systemic lupus erythematosus. Arthritis Rheum 2006;54(2):670–4. 47. Liu CC, Manzi S, Kao AH, et al. Reticulocytes bearing C4d as biomarkers of disease activity for systemic lupus eryhematosus. Arthritis Rheum 2005;52:3087–99. 48. Landolt-Marticorena C, Bonventi G, Lubovich A, et al. Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus. Ann Rheum Dis 2008 (online publication;Sept. 4). 49. Petri M, Stohl W, Chatham W, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008;58(8):2453–9. 50. Rovin BH, Song HJ, Brimingham DJ, et al. Urine chemokines as Biomarkers of human systemic lupus erythematosus activity.Journal of the American socity of nephrology. 2005; 16(2):467-473. 51. Palmieri V, Migliaresi P, Orefice M, et al. High prevalence of subclinical cardiovascular abnormalities in patients with systemic lupus erythematosus in spite of a very low clinical damage index. Nutr Metab Cardiovasc Dis 2009;19:234-40. 52. Westerweel PE, Luijten PK, Hoefer IE. et al. Haematopoietic and endothelial progenitor cells are deficient in quiescent systemic lupus erythematosus. Ann Rheum Dis 2007;66(7):865-870 53. Zhang C, Li K, Shi B, Wang X, et,al.Detection of serum β2-GPI–Lp(a) complexes in patients with systemic lupus erythematosus Clin Chim Acta. 2010 Mar;411(5-6):395-9. Epub 2009 Dec 21. 54. Huerta PT, Kowal C, DeGiorgio LA, et al. Immunity and behavior: antibodies alter emotion. Proc Natl Acad Sci U S A 2006;103(3):678–83. 55. Chan TM1, Tse KC, tang CSO et al. For diffuse proliferative lupus Nephritis Long-Term study of Mycophenolate Mofetil as continuous induction and Maintenance creat treatment of Journal of the American socity nephrology 2005 ;16(4):1076-1084 56. Diamanti AP，Rosado MM，Carsetti R，et a1．B cells in SLE: different biological drugs for different pathogenic mechanisms. [J]．Autoimmun Rev 2007;7(2):143-148． 57. Pepper R, Griffith M, Kirwan C, et al. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrology dialysis transplantation 2009 ;24(12):3717-23 58. Cardiel MH, Tumlin JA, Furie RA, et,al . LJP 394-90-09 Investigator Consortium: Abetimus sodium for renal flare in systemic lupus erythematosus. Results of a randomized, controlled phase III trial. Arthritis Rheum 2008; 58:2470-2480. 59. Booken N, Schumann T, Fuchslocher M, et,al. Successful therapy of discoid lupus erythematosus with Efalizumab. Hautarzt. 2009 May 14. [Epub ahead of print] 60. Tzellos TG, Kouvelas D. Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence-based evaluation. Eur J Clin Pharmacol 2008;64:337-341 61. Rother RP, Mojcik CF, McCroskery EW. Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosus. Lupus 2004 ;13, 328–334. 62. Atkinson C, Qiao F, Song H, et,al.Lowdose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice. J Immunol 2008; 180:1231-1238. 63. Bahjat FR, Pine PR, Reitsma A, et,al. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum 2008; 58:1433-1444. 64. Muller S, Monneaux F, Schall N, et,al. Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus. Results of an early phase II clinical trial. Arthritis Rheum 2008;58:3873-3883. 65. Burt RK, Traynor A, Statkute L, et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupuserythematosus. JAMA 2006; 295: 527–35. 66. Zandman-Goddard G, Levy Y, Shoenfeld Y. Intravenous immunoglobulin therapy and systemic lupus erythematosus. Clin Rev Allergy Immunol 2005; 29: 219–28.